SYSTEMATIC REVIEW ON MEDICAMENTS USED IN MANAGEMENT OF DIABETES MELLITUS
Diabetes has a global prevalence in developed countries and rapidly flexing its roots in middle-and low-income countries. According to the World Health Organization, it is a major cause of kidney collapse, heart problems, and lower limb amputation. Diabetes mellitus is a metabolic disorder showing an uncontrolled increase in blood glucose levels. To date, no permanent cure has been developed for the complete restoration of impaired glucose haemostasis. With the use of therapeutic agents and nontherapeutic agents, glucose levels can be kept in control for a very long time. The foremost goal of all current ongoing treatments is to control high blood glucose levels, reduction in elevated lipid levels, and delay in the progression of diabetes-related complications. Various therapeutics agents are developed in recent decades, which shown very promising results in the management of diabetes mellitus. These agents prescribed after reviewing the clinical symptoms and situation of an individual patient. This review compiles noteworthy information related to clinically approved medicaments for diabetes mellitus. Review emphasis on categorization, mechanism of action, noted adverse effects along with the physiological responses of used medicines to treat diabetes mellitus.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62-9.
3. Nyenwe E, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type diabetes. Metabolism 2011;60:1-23.
4. Pickup J. Human insulin. Br Med J 1986;292:155-7.
5. Brown H, Sanger F, Kitai R. The structure of pig and sheep insulin. Biochem J 1955;60:556-5.
6. Smith LF. Amino acid sequences of insulins. Diabetes 1972;21:457-60.
7. De Leeuw I, Delvigne C, Bekaert J. Insulin allergy treated with human insulin (recombinant DNA). Diabetes Care 1982;5:168-70.
8. Ghazavi MK, Johnston GA. Insulin allergy. Clin Dermatol 2011;29:300-5.
9. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2015;38:S8-16.
10. Yaturu S. Insulin therapies: current and future trends at dawn. World J Diabetes 2013;4:1-7.
11. Novak B, Metelko Z. New trends in insulin therapy. Diabetol Croat 2003;32:55-63.
12. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology. 12th Ed. New York: Tata McGraw-Hill; 2012.
13. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs NPH human insulin in type 1 diabetes, a meta-analysis. Diabetes Obes Metab 2009;11:372-8.
14. McGibbon A, Richardson C, Hernandez RNC, Dornan J. Pharmacotherapy in type 1 diabetes. Can J Diabetes 2013;37:S56-60.
15. Anonymous. DAFNE study group: training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Br Med J 2002;325:1-6.
16. Anonymous. The diabetes control and complications trial research group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415-27.
17. Gruesser M, Hartmann P, Schlottmann N, Joergens V. Structured treatment and teaching programme for type 2 diabetic patients on conventional insulin treatment: evaluation of reimbursement policy. Patient Educ Couns 1996;29:123-30.
18. Anonymous. The diabetes control and complications trial research group: Design and methodologic considerations for the feasibility phase. Diabetes 1986;35:530-45.
19. Anonymous. The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
20. Berghe GVD, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.
21. Al-Fifi SH. Intensive insulin treatment versus conventional regimen for adolescents with type 1 diabetes, benefits and risks. Saudi Med J 2003;24:485-7.
22. Cao SG, Ren JA, Shen B, Chen D, Zhou YB, Li JS. Intensive versus conventional insulin therapy in type 2 diabetes patients undergoing D2 gastrectomy for gastric cancer: a randomized controlled trial. World J Surg 2011;35:85-92.
23. Azevedo JRAD, Lima ERM, Cossetti RJD, Azevedo RPDA. Intensive insulin therapy versus conventional glycemic control in patients with acute neurological injury: a prospective controlled trial. Arq Neuro Psiquiatr 2007;65:733-8.
24. Rodger W. Insulin-dependent (type I) diabetes mellitus. Can Med Assoc J 1991;145:1227-37.
25. Kitabchi AE, Gosmanov AR. Safety of rapid-acting insulin analogs versus regular human insulin. Am J Med Sci 2012;344:136-41.
26. Joshi S, Joshi P. A review of insulin and insulin regimens in type 2 diabetes. S Afr Fam Pract 2009;51:97-102.
27. Noble SL, Johnston E, Walton B. Insulin lispro: a fast-acting insulin analo. Am Fam Physician 1998;57:279-86.
28. Tripathi KD. Essential of medical pharmacology. 7th ed. New Delhi: Jaypee Brother Medical Publisher; 2013.
29. Rave K, Klein O, Frick AD, Becker RHA. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006;29:1812-7.
30. Ozaki N, Oiso Y. Immunologic tolerance to the insulin analogue glulisine. Diabetes Care 2010;33:e39.
31. Urakami T, Kuwabara R, Habu M, Okuno M, Suzuki J, Takahashi S. Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes. J Diabetes Invest 2015;6:87-90.
32. Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab 2009;11:53-9.
33. Deckert T. Intermediate-acting insulin preparations: NPH and Lente. Diabetes Care 1980;3:623-6.
34. Vajo Z, Fawcwtt J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocr Rev 2001;22:706-17.
35. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005.
36. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000;23:813-9.
37. Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous insulin infusion and multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 2003;26:1321-2.
38. Jones DR. Insulin detemir: improving the predictability of glycemic control. Int J Obes 2004;28:S29-34.
39. Home P, Bartley P, Jones DR, Broutin HH, Heeg JE, Abrams P, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. Diabetes Care 2004;27:1081-7.
40. Kalra S, Farooqi MH, El-Houni AE. High-mix insulins. Indian J Endocrinol Metab 2015;19:686-90.
41. Turner HE, Matthews DR. The use of fixed-mixture insulin in clinical practice. Eur J Clin Pharmacol 2000;56:19-25.
42. Nathan DM. Finding new treatments for diabetes-how many, how fast, how good. N Engl J Med 2007;356:437-40.
43. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013;12:153-75.
44. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011;13:221-8.
45. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;16:159-69.
46. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-97.
47. American Diabetes Association. Summary of revisions to the 2011 clinical practice recommendations. Diabetes Care 2011;34:S3.
48. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 2014;20:953-66.
49. Ito H, Ishida H, Takeuchi Y, Antoku S, Abe M, Mifune M, et al. Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus. Nutr Metab 2010;7:1-9.
50. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012;35:446-54.
51. Viollet B, Guigas B, Sanz GN, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012;122:253-70.
52. Hur KY, Lee MS. New mechanisms of metformin action: focusing on mitochondria and the gut. J Diabetes Invest 2015;6:600-9.
53. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-? in mice. Diabetologia 2011;54:339-49.
54. Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 1992;131:1165-73.
55. Martin Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye Knudsen M, et al. Metformin improves health span and lifespan in mice. Nat Commun 2013;4:1-9.
56. Anonymous. The diabetes prevention program research group. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care 2012;35:731-7.
57. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
58. Gavin JR. Symposium on glyburide: summary and closing remarks. Am J Med 1990;89:51S-3S.
59. Bosenberg LH, Zyl DGV. The mechanism of action of oral antidiabetic drugs: a review of recent literature. JEMDSA 2008;13:80-8.
60. Ibrahim R. Diabetes mellitus type 2: a review of oral treatment options. Int J Pharm Pharma Sci 2010;2:21-30.
61. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocr Diab 1996;104:1-9.
62. Aguilar Bryan L, Nichols CG, Wechsler SW, Clement JP, Boyd AE, Gonzalez G, et al. Cloning the ? cell high-affinity sulphonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-6.
63. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002;51:S368-76.
64. Jackson L, Robertson L. Sulphonylureas (specifically glibenclamide) and their correct dosage. S Afr Med J 1989;76:286-9.
65. Li Y, Hu Y, Ley SH, Rajpathak S, Hu FB. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care 2014;37:3106-13.
66. Bosenberg LH, Zyl DGV. The mechanism of action of oral antidiabetic drugs: a review of recent literature. J Endocr Metab Diab S Afr 2008;13:80-8.
67. Gerich JE. Oral hypoglycemic agent. N Engl J Med 1989;321:1231-45.
68. Ambavane V, Patil R, Ainapure SS. Repaglinide, a short-acting insulin secretagogues for postprandial hyperglycaemia. Drug Rev 2002;48:246-8.
69. Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, et al. Repaglinide versus nateglinide monotherapy. Diabetes Care 2004;27:1265-70.
70. Murad HAS, Hamza M, Hamza SA. Repaglinide as a safe alternative against hypoglycemia in fasting elderly diabetic patients: a single-blinded, placebo-controlled, six-period, cross-over study. Afr J Pharm Pharmacol 2013;7:763-9.
71. Tsang MW. The management of type 2 diabetic patients with hypoglycaemic agents. ISRN Endocrinol 2012:1-9. https://doi.org/10.5402/2012/601380
72. Campbell I. Oral antidiabetic drugs: their properties and recommended use. Prescriber 2007;18:56-74.
73. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
74. Hauner H. The mode of action of thiazolidinediones. Diabetes/Metab Res Rev 2002;18:S10-5.
75. Diaz Delfin J, Morales M, Caelle CH. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor ? by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 2007;56:1865-71.
76. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care 2004;27:256-63.
77. Flanagan PR, Forstner GG. Purification of rat intestinal maltase/glucoamylase and its anomalous dissociation either by heat or by low pH. Biochem J 1978;173:553-6.
78. Derosa G, Maffioli P. ?-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci 2012;9:899-906.
79. Van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manage 2008;4:1189-95.
80. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Weel CV. ?-glucosidase inhibitors for patients with type 2 diabetes. Diabetes Care 2005;28:154-63.
81. Scheen AJ. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab 1998;24:311?20.
82. Kao CC, Wu PC, Wu CH, Chen LK, Chen HH, Wu MS, et al. Risk of liver injury after ?-glucosidase inhibitor therapy in advanced chronic kidney disease patients. Sci Rep 2016;6:1-6.
83. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010;1:8-23.
84. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol 2004;287:E199-206.
85. Schweizer A, Foley JE, Kothny W, Ahren B. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Vasc Health Risk Manage 2013;9:57-64.
86. Wheeler MB, Gelling RW, McIntosh CH, Georgiou J, Brown JC, Pederson RA. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 1995;36:4629-39.
87. Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. J Am Board Fam Med 2006;19:612-20.
88. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585-96.
89. Yavropoulou MP, Pikilidou M, Kotsa K, Michopoulos A, Papakonstantinou E, Yovos JG. Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. J Diabetes Metab Disord 2015;14:1-7.
90. Kutoh E. Sitagliptin is effective and safe as an add-on to insulin in patients with absolute insulin deficiency: a case series. J Med Case Rep 2011;5:1-5.
91. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
92. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.
93. Ahren B, Landin Olsson M, Jansson PA, Svenson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84.
94. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011;13:775-83.
95. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007;92:4165-71.
96. Yavropoulou MP, Pikilidou M, Kotsa K, Michopoulos A, Papakonstantinou E, Yovos JG. Efficacy and tolerability of vildagliptin as first-line treatment in patients with diabetes type 2 in an outpatient setting. J Diabetes Metab Disord 2015;14:1-7.
97. Jeon JH, Oh TK. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J 2011;35:529-35.
98. Neumiller JJ, Campbell RK. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm 2010;67:1515-25.
99. Dave DJ. Saxagliptin: a dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother 2011;2:230-5.
100. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71-80.
101. Anonymous. Saxagliptin (Onglyza) for type 2 diabetes. Med Lett Drugs Ther 2009;51:85-6.
102. DeFronzo RA, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55.
103. Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, et al. Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr 2014;6:1-9.
104. Ott C, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P, et al. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol 2014;13:1-9.
105. Peters JU. 11 y of cyanopyrrolidines as DPP-IV inhibitors. Curr Top Med Chem 2007;7:579-95.
106. Deacon CF, Holst JJ. Linagliptin. A xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Invest Drugs 2010;19:133-40.
107. Guedes EP, Hohl A, Melo TG, Lauand F. Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetol Metab Syndr 2013;5:1-7.
108. Gallwitz B. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Ther Adv Endocrinol Metab 2013;4:95-105.
109. Kern M, Kloting N, Heiko G, Niessen HG, Thomas L, Stiller D, et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One 2012;7:1-10.
110. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67.
111. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care 2008;31:2315-7.
112. Raalte DHV, Genugten REV, Eliasson B, Goede DLM, Mari A, Tura A, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of ?-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol 2014;170:565-74.
113. Mashitani T, Noguchi R, Okura Y, Namisaki T, Mitoro A, Ishii H. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep 2016;4:183-7.
114. Ndefo UA, Okoli O, Erowele G. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. Am J Health Syst Pharm 2014;71:103-9.
115. Hood R, Valentine V, Mac S, Polonsky WH. Use of exenatide in patients with type 2 diabetes. Diabetes Spectr 2006;19:181-6.
116. Nielsen LL, Young AA, Parkes D. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88.
117. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of Exenatide (exendin-4) on glycemic control and weight over 30 w in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
118. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skoth TV, et al. Efficacy of Liraglutide for weight loss. Among patients with type 2 diabetes: the scale diabetes randomized clinical trial. JAMA 2015;314:687-99.
119. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
120. Garber A, Henry R, Ratner R, Garcia Hemandez PA, Rodriguez Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2008;373:473-81.
121. Clements JN, Shealy KM. Liraglutide, an injectable option for the management of obesity. Ann Pharmacother 2015;49:938-44.
122. Kuhadiya N, Malik R, Bellini N, Patterson J, Traina A, Makdissi A, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 2013;19:963-7.
123. Blair HA, Keating GM. Albiglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs 2015;75:651-63.
124. Rendell MS. Albiglutide for the management of type 2 diabetes. Expert Rev Endocrinol Metab 2018;13:1-8.
125. Burness CB, Scott LJ. Dulaglutide: a review in type 2 diabetes. Bio Drugs 2015;29:407-18.
126. Wasir JS, Mithal A, Agarwal P, Mittal A. Once-weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India. Indian J Endocr Metab 2018;22:728-34.
127. Gomez Peralta F, Abreu C. Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. Drug Des Dev Ther 2019;13:731-8.
128. Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care 2013;36:498-504.
129. Danial E Baker, DE Levien TL. Lixisenatide. Hosp Pharm 2017;52:65-80.
130. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164:58-64.
131. Okere AN, Montesdeoca J, Glasper A, Diaby V. An evaluation of the clinical therapeutic effect of Lixisenatide in type 2 diabetes patients: a systematic literature review. Curr Diabetes Rev 2018;14:363-75.
132. Kalra S. Sodium-glucose co-transporter-2 (sglt2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 2014;5:355-66.
133. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Dev Ther 2014;8:1335-80.
134. Nakajima H, Okada S, Mohri T, Kanda E, Inaba N4, Hirasawa Y, et al. Dapaglifozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient-reported outcome study (PRO study). Diabetol Metab Syndr 2018;10:1-11.
135. Anderson SL. Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf 2014;5:242-54.
136. Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review-safety and efficacy profile in patients with T2DM. Diabetes, Metab Syndr Obes: Targets Ther 2019;12:209-15.
137. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015;38:2258-65.
138. Sharma V, Sharma S, Jaiswal S, Ghanghas RR, Boddepalli D, Sharma AK. Ertugliflozin: a novel anti-diabetic drug. Int J Basic Clin Pharmacol 2018;7:1-4.
139. Hu J, Deng A, Zhao Y. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes. Expert Opin Pharmacother 2018;19:1841-7.
140. Neumiller JJ. Empagliflozin: a new sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context 2014;3:3-18.
141. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
142. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology and clinical potential. Pharmacol Rev 2015;67:564-600.
143. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Dev Ther 2008;2:203-14.
144. Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother 2011;12:1439-51.
145. DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011;34:789-94.
146. Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. Indian J Endocrinol Metab 2011;15:S17-24.
147. Kandasamy K, Rajagopal SS, Ramalingam KK, Krishnan K. Prevalence of diagnosed and undiagnosed diabetes in a rural community: a home-based screening. Asian J Pharm Clin Res 2018;11:454-7.
148. Kumar M, Shivgotra VK, Nanda H. Gender-wise prevalence of diabetes among the Indian population: a meta-analysis using R software. J Crit Rev 2020;7:683-91.
149. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors 2001. JAMA 2003;289:76-9.
150. Jain R, Jain P, Jain P. A review on treatment and prevention of diabetes mellitus. Int J Curr Pharm Res 2016;8:16-8.
151. Poornima KN, Kanimozhi S, Karthick N, Saravanan A, Padmavathi R. Skeletal muscle: one of the silent targets of diabetic complications. Asian J Pharm Clin Res 2018;9:206-8.
152. Fowle MJ. Diabetes treatment, part 1: diet and exercise. Clin Diabetes 2007;25:105-9.
153. Rabasa Lhoret R, Garon J, Langelier H, Poisson D, Chiasson JL. Effects of the meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultra lente-regular) insulin regimen. Diabetes Care 1999;22:667-73.
154. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. Nutrition principles and recommendations in diabetes. Diabetes Care 2004;27:S36-46.
155. Gannon MC, Nuttall JA, Damberg G, Gupta V, Nuttall FQ. Effect of protein ingestion on the glucose appearance rate in people with type 2 diabetes. J Clin Endocrinol Metab 2001;86:1040-7.
156. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie Rosett J, Kulkarni K, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American diabetes association, the North American association for the study of obesity, and the American Society for clinical nutrition. Diabetes Care 2004;27:2067-73.
157. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001;286:1218-27.
158. Sigal RJ, Kenny GP, Wasserman DH, Castaneda Sceppa C, White RD. Physical activity/exercise and type 2 diabetes. Diabetes Care 2006;29:1433-8.
159. Marwick TH, Hordern MD, Miller T, Chyun DA, Bertoni AG, Blumenthal RS, et al. Exercise training for type 2 diabetes mellitus impact on the cardiovascular risk a scientific statement from the American heart association. Circulation 2009;119:3244-62.
160. Presetiawati IIN, Andrajati R, Sauriasari R. Effectiveness of a medication booklet and counseling on treatment adherence in type 2 diabetes mellitus patients. Int J Appl Pharm 2017;9:27-31.
This work is licensed under a Creative Commons Attribution 4.0 International License.